ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
122.098,09
-0,50%
S&P 500
5.277,51
0,80%
US Dollar vs BRL
5,2463
0,00%
Bitcoin
67.689,98
-0,05%
Brent Oil
81,295
0,00%
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. LianBio (LIAN)

  7. LianBio (LIAN) Notícias

LIAN

LianBio (LIAN)

LianBio
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:LIAN
DataHoraFonteTítuloCódigoCompanhia
11/03/202408:51Edgar (US Regulatory)Form 25 - Notification of the removal from listing and registration of matured, redeemed or retired securitiesNASDAQ:LIANLianBio
28/02/202409:00GlobeNewswire Inc.LianBio Announces Voluntarily Delisting from NasdaqNASDAQ:LIANLianBio
20/02/202418:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LIANLianBio
13/02/202409:04Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LIANLianBio
13/02/202409:00GlobeNewswire Inc.LianBio Announces Completion of Strategic ReviewNASDAQ:LIANLianBio
08/01/202408:13Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:LIANLianBio
26/12/202318:10Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:LIANLianBio
26/12/202316:40AllPennyStocks.comBiotech Finds Success Following Holiday WeekendNASDAQ:LIANLianBio
26/12/202304:00GlobeNewswire Inc.LianBio Enters into Agreement Assigning its Rights for NBTXR3 in China and Other Asian MarketsNASDAQ:LIANLianBio
20/12/202310:00GlobeNewswire Inc.LianBio Announces Departure of Chief Financial OfficerNASDAQ:LIANLianBio
19/12/202318:05GlobeNewswire Inc.LianBio Announces Departure of Chief Executive OfficerNASDAQ:LIANLianBio
06/12/202318:05GlobeNewswire Inc.LianBio’s Board of Directors Unanimously Determines not to Pursue Unsolicited Proposal from Concentra BiosciencesNASDAQ:LIANLianBio
01/12/202318:05GlobeNewswire Inc.LianBio Confirms Receipt of Unsolicited Proposal from Concentra BiosciencesNASDAQ:LIANLianBio
13/11/202318:28Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LIANLianBio
13/11/202318:05GlobeNewswire Inc.LianBio Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:LIANLianBio
30/10/202317:05GlobeNewswire Inc.LianBio Announces Topline Results from Phase 3 LIBRA Trial of TP-03 in Chinese Patients with Demodex BlepharitisNASDAQ:LIANLianBio
25/10/202317:05GlobeNewswire Inc.LianBio Announces Presentation of Data from Phase 2a Study of Infigratinib in Patients with Gastric Cancer at ESMO Congress 2023NASDAQ:LIANLianBio
24/10/202311:25AllPennyStocks.comBiotech Shares Soar PremarketNASDAQ:LIANLianBio
24/10/202310:22Dow Jones NewsLianBio Shares Soar Premarket on Strategic Review, End of Bristol PactNASDAQ:LIANLianBio
24/10/202307:59GlobeNewswire Inc.LianBio Enters into Agreement with Bristol Myers Squibb for Mavacamten in China and Other Asian MarketsNASDAQ:LIANLianBio
28/08/202317:05GlobeNewswire Inc.LianBio Announces Results from Phase 3 EXPLORER-CN Trial of Mavacamten Presented at the European Society of Cardiology Congress and Simultaneous Publication in JAMA CardiologyNASDAQ:LIANLianBio
14/08/202317:05GlobeNewswire Inc.LianBio Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:LIANLianBio
03/08/202317:05GlobeNewswire Inc.LianBio Announces First Patient Treated in Phase 1 Trial of SHP2 Inhibitor BBP-398 in Combination with Osimertinib in Patients with Non-Small Cell Lung Cancer with EGFR MutationsNASDAQ:LIANLianBio
26/07/202309:30GlobeNewswire Inc.LianBio Partner Tarsus Pharmaceuticals Announces U.S. FDA Approval of XDEMVY™ (lotilaner ophthalmic solution) 0.25% for the Treatment of Demodex BlepharitisNASDAQ:LIANLianBio
18/07/202309:00GlobeNewswire Inc.LianBio Partner NANOBIOTIX Enters into License Agreement with Janssen for Radioenhancer NBTXR3, with LianBio Retaining Development and Commercialization Rights in Greater China, South Korea, Singapore and ThailandNASDAQ:LIANLianBio
17/07/202307:00GlobeNewswire Inc.LianBio Announces Phase 3 EXPLORER-CN Data Accepted for Late-Breaking Presentation at the European Society of Cardiology Congress 2023NASDAQ:LIANLianBio
12/07/202309:00GlobeNewswire Inc.LianBio Announces Clinical Supply Agreement with AstraZeneca in China to Evaluate BBP-398 in Combination with Osimertinib in Patients with Non-Small Cell Lung Cancer with EGFR MutationsNASDAQ:LIANLianBio
26/06/202309:00GlobeNewswire Inc.LianBio Announces Marketing Approval of CAMZYOS® (mavacamten) in SingaporeNASDAQ:LIANLianBio
23/06/202317:23Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:LIANLianBio
23/06/202317:18Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:LIANLianBio
 Apresentando as notícias mais relevantes sobre:NASDAQ:LIAN

Seu Histórico Recente

AMEX
GIG
GigPeak, Inc.
KOSPI
005430
Korean Air Terminal Serv...
USOTC
BYRLF
BII Railway Transportati... (PK)
USOTC
IKTO
iTokk (CE)
ASX
PE1
Pengana Private Equity
EU
EUSN
Euronext USA NR
NASDAQ
MGRC
McGrath RentCorp
TSXV
AGC
Amarillo Gold
EU
APHSS
Paris Aphp0%18apr29
TSXV
RJX.A
RJK Explorations
EU
ALSAS
Stradim Espac Fin
COIN
PRSNETH
Persona
LSE
AX92
Pmf2024-1 60 A
BIT
P1HZM8
BNP Paribas Issuance
BIT
UB26FM
UniCredit Bank
BOV
UNIP3M
UNIPAR ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados